Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
483
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma

Yuqin Songa Department of Lymphoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China
,
Jianyong Lib Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Keshu Zhouc Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
,
Xiaoyan Ked Department of Hematology, Peking University Third Hospital, Beijing, China
,
Zhen Caie Department of Hematology, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China
,
Huilai Zhangf Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
,
Tingting Yaog AstraZeneca, Shanghai, China
,
Zhen Xiag AstraZeneca, Shanghai, China
,
Yiqiu Wangg AstraZeneca, Shanghai, China
,
Peiqiong Laig AstraZeneca, Shanghai, China
,
Xiaofeng Liug AstraZeneca, Shanghai, China
&
Jun Zhua Department of Lymphoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, ChinaCorrespondence[email protected]
 show all
Pages 647-652 | Received 20 Jul 2023, Accepted 21 Jan 2024, Published online: 01 Apr 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.